Serum chemerin levels are associated with the presence and extent of coronary artery disease.

Department of Cardiology, Beijing Armed Police Corps Hospital, China.
Coronary artery disease (Impact Factor: 1.56). 07/2012; 23(6):412-6. DOI: 10.1097/MCA.0b013e3283576a60
Source: PubMed

ABSTRACT The aim of the study was to examine whether serum chemerin levels are associated with the presence and the extent of coronary artery disease (CAD).
A total of 132 patients with CAD and 56 patients without CAD who underwent coronary angiography for the evaluation of CAD were enrolled in this study. Serum levels of chemerin were measured using an enzyme-linked immunosorbent assay.
Serum chemerin levels were significantly elevated in CAD patients compared with those without CAD. Multivariate logistic regression analysis showed that serum chemerin levels were significantly associated with the presence of CAD. In CAD patients, chemerin was positively correlated with BMI (r=0.274, P=0.001) and triglycerides (r=0.190, P=0.029), and yet correlated with low-density lipoprotein-cholesterol (r=0.228, P=0.008); the association of chemerin with triglycerides and low-density lipoprotein-cholesterol remained significant after adjusting for BMI (P<0.05 and P<0.01). At multiple stepwise regression analysis, serum chemerin levels were an independent predictor of the stenosis score (β=0.193, P=0.034).
Our data suggest that increased chemerin levels are associated with the presence of CAD and that serum chemerin levels may reflect the extent of coronary atherosclerosis.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Chemerin is a peptide chemoattractant for macrophages and an adipokine regulating adipocyte differentiation and metabolism. Plasma chemerin is increased in chronic inflammatory diseases and in obesity. As inflammation and obesity are risk factors for coronary artery disease (CAD), we investigated possible associations of plasma chemerin with inflammatory markers and atherosclerosis in a CAD case-control study (n=470). Chemerin levels were associated with C-reactive protein, BMI and LDL levels, and negatively associated with HDL levels. Mean plasma chemerin levels were similar in controls and CAD patients but significantly higher in CAD patients not taking low dose aspirin. To investigate the mechanism of chemerin reduction by aspirin, we analyzed chemerin expression in hepatocytes and adipocytes treated with aspirin in the presence and absence of inflammatory cytokines. Chemerin expression was upregulated by pro-inflammatory stimuli in adipocytes but not in hepatocytes. Treatment of stimulated hepatocytes and adipocytes with aspirin did not affect chemerin expression. However, treatment of inflammatory M1 macrophages with aspirin reduced secretion of the pro-inflammatory cytokines IL-1β and IL-6, and increased secretion of the anti-inflammatory IL-10. In summary, we show that plasma chemerin levels are associated with markers of inflammation and that they are significantly higher in CAD patients not treated with low dose aspirin. In addition, we show that low dose aspirin treatment reduces pro-inflammatory cytokine secretion by macrophages, which may lead to reduced chemerin secretion by adipocytes and may be a reason for the lower chemerin levels in the circulation of CAD patients on low dose aspirin.
    Atherosclerosis 05/2014; 235(2):256-262. · 3.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract We aimed to investigate whether overweight/obesity is associated with omentin and chemerin. The study group consisted of 81 women with Polycystic ovarian syndrome (PCOS) (41 lean, BMI < 25 kg/m(2) and 40 overweight or obese, BMI > 25 kg/m(2)) and 61 healthy subjects (31 lean, BMI < 25 kg/m(2) and 30 overweight or obese, BMI > 25 kg/m(2); control group). The clinical, endocrine, metabolic parameters, plasma omentin and chemerin levels were measured in patients and compared to control. In all subjects with PCOS (n = 80), serum chemerin levels were higher compared with those of the controls (n = 58) (7.71 ± 1.78 ng/mL versus 6.94 ± 0.82 ng/mL, p = 0.003). However, serum omentin levels were not significantly different between the PCOS subjects and the controls (1.55 ± 0.43 ng/mL versus 1.69 ± 0.37 ng/mL, p = 0.056). The mean chemerin concentrations were significantly elevated in the obese PCOS group compared with the obese control subjects (8.98 ± 1.45 ng/mL versus 7.02 ± 0.67 ng/mL, p = 0.000) and the nonobese PCOS group compared with the obese control subjects (6.57 ± 1.17 ng/mL versus 7.02 ± 0.67 ng/mL, p = 0.000). In conclusion, fat mass seems to be the main determinant factor of increased chemerin and decreased omentin in women with PCOS.
    Gynecological Endocrinology 02/2014; · 1.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Depending on their anatomical location, different fat depots have a different capacity to produce bioactive peptides, called adipokines. Adipokines produced by periadventitial fat have been implicated in the pathogenesis of vascular disease, including atherosclerosis. Chemerin is an adipokine with an established role in immunity, adipose tissue function and metabolism, acting in autocrine, paracrine and endocrine manners. We investigated the protein expression of chemerin and its receptor, CMKLR1, in human aortas, coronary vessels and the respective periadventitial adipose tissue and correlated their expression with the presence of atherosclerosis. Immunohistochemistry for chemerin and CMKLR1 was performed on human aortic and coronary artery samples including the periadventitial adipose tissue. Aortic and coronary atherosclerotic lesions were assessed using the AHA classification. Chemerin immunopositivity was noticed in both periadventitial fat depots, in vascular smooth muscle cells and foam cells in atherosclerotic lesions. Periadventitial fat and foam cell chemerin immunopositivity was statistically significantly correlated with the severity of atherosclerosis in both locations. CMKLR1 was expressed in vascular smooth muscle cells and foam cells in aortic and coronary vessels with atherosclerotic lesions. CMKLR1 immunostaining in foam cells was statistically significantly correlated with aortic atherosclerosis. Our results lend some support to a presumable role of locally produced chemerin in the progression of atherosclerotic lesions, possibly acting through its CMKLR1 receptor. Further research will elucidate the role of chemerin signaling in atherosclerosis.
    BMC Cardiovascular Disorders 04/2014; 14(1):56. · 1.46 Impact Factor